Carnegie Investment Counsel Boosts Holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Carnegie Investment Counsel boosted its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 6.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 101,106 shares of the exchange traded fund’s stock after acquiring an additional 5,683 shares during the period. Carnegie Investment Counsel’s holdings in SPDR S&P Biotech ETF were worth $9,106,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its holdings in shares of SPDR S&P Biotech ETF by 15.4% in the second quarter. Bank of New York Mellon Corp now owns 5,590 shares of the exchange traded fund’s stock worth $518,000 after buying an additional 744 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 12.5% in the second quarter. Envestnet Asset Management Inc. now owns 186,400 shares of the exchange traded fund’s stock worth $17,281,000 after buying an additional 20,685 shares during the last quarter. Citizens Financial Group Inc. RI raised its holdings in shares of SPDR S&P Biotech ETF by 26.2% in the second quarter. Citizens Financial Group Inc. RI now owns 3,971 shares of the exchange traded fund’s stock worth $368,000 after buying an additional 825 shares during the last quarter. Moors & Cabot Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 2.4% in the second quarter. Moors & Cabot Inc. now owns 6,937 shares of the exchange traded fund’s stock worth $643,000 after buying an additional 162 shares during the last quarter. Finally, Pekin Hardy Strauss Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 10.0% in the second quarter. Pekin Hardy Strauss Inc. now owns 2,480 shares of the exchange traded fund’s stock worth $230,000 after buying an additional 225 shares during the last quarter.

SPDR S&P Biotech ETF Price Performance

Shares of SPDR S&P Biotech ETF stock opened at $87.89 on Friday. The firm has a fifty day moving average price of $94.72 and a 200 day moving average price of $97.00. SPDR S&P Biotech ETF has a 1 year low of $81.14 and a 1 year high of $105.47. The stock has a market cap of $6.70 billion, a PE ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.